The following NCCTG cancer treatment clinical trials are currently active. You may click on the trial number to link to a detailed description on PDQ, the National Cancer Institute's Web site for clinical trials.
| BIG2-06 | BIG 2-06/N063D/EGF106708, ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study - A randomised, multi-centre, open label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer |
| E5103 | A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer |
| MA.17 | A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women With Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen |
| N0733 | Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 in Patients with HER2 Positive, Breast Cancer Previously Treated with Trastuzumab and an Anthracycline and/or a Taxane |
For more information, please discuss these trials with your physician, contact the NCCTG Operations Office or contact an NCCTG treating location near you.
Return to list of Cancer Treatment Trials
© Copyright 2008, NCCTG